Uniqure (NASDAQ:QURE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other analysts have also recently issued reports on the company. HC Wainwright raised their price objective on Uniqure from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, September 24th. BidaskClub cut Uniqure from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 28th. Cantor Fitzgerald set a $58.00 target price on Uniqure and gave the stock a “buy” rating in a research note on Thursday, August 23rd. Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. Finally, Cowen reiterated a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $44.90.
Shares of QURE traded down $0.69 during mid-day trading on Wednesday, reaching $27.41. The company’s stock had a trading volume of 1,535 shares, compared to its average volume of 328,073. Uniqure has a 1-year low of $11.55 and a 1-year high of $43.23. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.57 and a beta of 0.26. The company has a quick ratio of 8.36, a current ratio of 8.36 and a debt-to-equity ratio of 0.06.
Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.04. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. The company had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.37 million. As a group, analysts expect that Uniqure will post -2.44 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP increased its stake in shares of Uniqure by 0.7% during the second quarter. RTW Investments LP now owns 409,370 shares of the biotechnology company’s stock worth $15,474,000 after purchasing an additional 2,703 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 4,700 shares during the period. Gagnon Securities LLC bought a new position in shares of Uniqure during the second quarter worth approximately $209,000. Financial Gravity Wealth Inc. bought a new position in shares of Uniqure during the first quarter worth approximately $177,000. Finally, Atria Investments LLC bought a new position in Uniqure during the 2nd quarter worth $247,000. Institutional investors own 59.13% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
See Also: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.